Please ensure Javascript is enabled for purposes of website accessibility

Why STAAR Surgical Company Shares Are Seeing Big Gains

By Sean Williams – Mar 17, 2014 at 8:02AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

STAAR Surgical surges after a positive FDA panel review. Can shares head even higher?

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of STAAR Surgical (STAA 0.22%), a developer of implantable lenses for the eye that treat astigmatism and myopia, surged as much as 27% after receiving a positive view from the Food and Drug Administration's panel on its Visian Toric implantable collamer lens, or Visian TICL.

So what: According to STAAR Surgical's press release, the FDA's Ophthalmic Devices Panel of the Medical Devices Advisory Committee voted favorably on all three questions posed to it by the FDA's division of Ophthalmic, Neurological, and Ear, Nose and Throat Devices. The questions primarily revolved around the safety of Visian TICL and its benefits relative to its risks. As STAAR Surgical's release also noted, the Visian TICL would allow surgeons to correct astigmatism and myopia during a single procedure. Following this favorable news, research firm Canaccord Genuity boosted its rating on STAAR Surgical to buy from hold with a price target of $20, implying 30% upside to Friday's closing price.

Now what: This is good news for STAAR Surgical, which has done an efficient job of expanding its product pipeline and indications in what looks to be a rapidly growing ophthalmic market over the coming decades given the retirement of baby boomers. It's perhaps a bit concerning from a shareholder's perspective that STAAR has missed Wall Street's EPS estimates in the past three quarters, but given its double-digit revenue growth potential, it's a company I'd suggest adding to your watchlist and keeping an eye on (no pun intended), especially if it has any significant dips.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any companies mentioned in this article. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.